Altimmune's pemvidutide reduces heavy drinking days in Phase 2 trial
ALT•Altimmune said its Phase 2 RECLAIM trial found pemvidutide significantly reduced heavy drinking compared with placebo and improved abstinence in adults with moderate-to-severe alcohol use disorder. The company said an FDA meeting is scheduled for December to discuss Phase 3 program design.
1. Trial results
Altimmune presented positive Phase 2 RECLAIM results for investigational pemvidutide in adults with moderate-to-severe alcohol use disorder at AASLD’s Liver Meeting 2026. The trial met its primary endpoint, with treatment significantly reducing heavy drinking versus placebo; abstinence also improved. Pemvidutide was generally well tolerated, with mostly mild-to-moderate adverse events and discontinuation rates comparable with placebo.
2. Other study and next steps
Additional Phase 2b IMPACT results showed improvements in liver fibrosis markers in patients with metabolic dysfunction-associated steatohepatitis. Altimmune said an FDA meeting is scheduled for December to discuss the design of a Phase 3 registrational program for alcohol use disorder.
